Strategic Partnerships Recent collaboration with Thermo Fisher Scientific as a global authorized distributor for AgriSeq products signals openness to ecosystem partnerships and channel-driven growth. This presents a sales opening to align complementary genomics and diagnostics solutions with Sedia's distribution network and jointly pursue expanded market reach.

Global Qualifications WHO Pre-Qualification for the Asanté HIV-1/2 Oral Fluid Test highlights credibility in international markets and potential demand from public health programs. A sales opportunity exists to position these diagnostics to NGOs, clinics, and procurement agencies seeking pre-qualified, reliable testing solutions.

Quality Emphasis ISO 13485 certification for HIV in vitro diagnostics demonstrates a commitment to high-quality manufacturing standards. This can be leveraged to pursue enterprise customers and distributors who require certified processes, enabling higher-value contracts and longer-term partnerships.

Expanded Genomics Capabilities Past acquisition and integration of Floragenex and the launch of SARS-CoV-2 whole genome sequencing services indicate robust genomics and sequencing capabilities. This supports cross-sell opportunities to labs and research institutions needing sequencing, bioinformatics, or genomic surveillance services.

Mid-Market Focus Revenue in the single-digit millions with a lean employee base suggests agility and potential for scalable pilots with mid-size healthcare providers, diagnostic labs, and biopharma companies seeking targeted, cost-effective solutions without large enterprise onboarding. This is a fertile area for initial partnerships and pilot programs.